Levofloxacin is NOT recommended as a primary treatment option for Acinetobacter baumannii infections
Levofloxacin should not be used for A. baumannii infections due to widespread resistance and lack of guideline support; instead, use polymyxins (colistin or polymyxin B) for carbapenem-resistant strains or carbapenems for susceptible strains, with sulbactam as an alternative when MIC ≤4 mg/L.
Why Levofloxacin is Inappropriate
The available guidelines 1, 2 specifically address A. baumannii treatment but notably exclude fluoroquinolones like levofloxacin from their recommended antimicrobial regimens. The comprehensive ICU task force guidelines 1 provide detailed dosing tables for multiple antibiotics (carbapenems, polymyxins, sulbactam, tigecycline, rifampicin, fosfomycin) but levofloxacin is conspicuously absent from these recommendations.
One small interim study 2 mentioned levofloxacin only as an adjunct combined with ampicillin-sulbactam or colistin in a specific ICU setting, not as monotherapy. This reflects the reality that A. baumannii, particularly multidrug-resistant strains, typically exhibits high-level fluoroquinolone resistance.
Recommended Treatment Approach for A. baumannii
For Carbapenem-Susceptible Strains (in areas with low resistance rates):
For Carbapenem-Resistant A. baumannii (CRAB):
First-line options:
Polymyxin E (Colistin):
Polymyxin B:
- Loading dose: 2-2.5 mg/kg 1
- Maintenance: 1.5-3 mg/kg/day in 2 doses
Alternative (when MIC ≤4 mg/L):
- Sulbactam: 9-12 g/day in 3-4 divided doses 1
Renal Dose Adjustments
While the guidelines 1 emphasize that loading doses should be given regardless of renal function, maintenance doses require adjustment for polymyxins and carbapenems based on creatinine clearance. Specific adjustment tables should be consulted for each agent.
Critical Pitfalls to Avoid
Do not use fluoroquinolones as empiric or directed therapy for A. baumannii unless specifically documented susceptibility with low MIC values and no other options exist
Never skip the loading dose of colistin—suboptimal plasma concentrations for 2-3 days increase mortality risk 1
Avoid tigecycline or sulbactam monotherapy for empirical treatment 1
Do not use standard doses for severe infections—higher doses are required (e.g., meropenem 2g q8h, not standard dosing) 1
When to Consider Empiric A. baumannii Coverage
Empiric coverage is warranted in 1:
- Active A. baumannii outbreak situations
- Previously colonized patients
- Endemic ICU settings with high A. baumannii rates
- Patients with multiple risk factors (prolonged ICU stay, mechanical ventilation, prior broad-spectrum antibiotics)
The absence of levofloxacin from evidence-based A. baumannii treatment guidelines reflects its inadequate activity against this pathogen, particularly multidrug-resistant strains that dominate current epidemiology.